This is a 2-arm, single-center, open-label, randomized, active-controlled study to compare the safety and efficacy of luteal phase replacement with DR-2011 to progesterone vaginal gel over an 18-day treatment period. Patients will also be required to use an estrogen patch during the course of the study. The overall study duration for each patient will be approximately 1½ months.

Luteal phase replacement will be monitored by endometrial biopsy on Cycle Day 25 or 26. In addition, serum hormonal levels will be measured at Screening and at designated times from Cycle Day 14 to 31.

Inclusion Criteria:

• Not pregnant
• Clinically or medically-induced non-functioning or surgically removed ovaries
• Clinical investigator believes patient would be eligible for oocyte donation

Exclusion Criteria:

• Any contraindication to progesterone or estrogen therapy
• Undiagnosed vaginal bleeding
• History of uterine fibroids or any other conditions that could adversely affect pregnancy success
• Hysterectomy
• Any contraindication to vaginal drug delivery systems